Sidley advised Tricida, Inc. (Tricida; Nasdaq: TCDA) on a fast-moving registered direct equity financing. The financing includes the issuance of common stock and warrants at a premium to the previous market close. The funds raised will be used to extend Tricida’s financial runway and to continue to execute on their VALOR-CKD trial. Tricida is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally administered polymer designed to slow CKD progression in patients with metabolic acidosis and CKD.
The Sidley team was led by Private Equity partner Geoff Levin and included Capital Markets counsel Istvan Hajdu, M&A associates Nikita Ponomarev and Connor Grant-Knight, as well as Capital Markets associates Kostian Ciko and Amelia Barnes; with support from Capital Markets partner Michael Kohler and senior counsel Michael Hyatte; Securities Enforcement and Regulatory partner David Katz and counsel Benjamin Nager; and Tax partner Suresh Advani.